|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1994-11-3
|
|
pubmed:abstractText |
We report the outcome of a Phase II study of a cohort of patients with high-grade glioma treated with accelerated hyperfractionated radiation and the radiation sensitizer, iododeoxyuridine (IdUrd).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
583-90
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:7928489-Adult,
pubmed-meshheading:7928489-Aged,
pubmed-meshheading:7928489-Astrocytoma,
pubmed-meshheading:7928489-Brain Neoplasms,
pubmed-meshheading:7928489-Combined Modality Therapy,
pubmed-meshheading:7928489-Female,
pubmed-meshheading:7928489-Glioblastoma,
pubmed-meshheading:7928489-Humans,
pubmed-meshheading:7928489-Idoxuridine,
pubmed-meshheading:7928489-Male,
pubmed-meshheading:7928489-Middle Aged,
pubmed-meshheading:7928489-Radiation-Sensitizing Agents,
pubmed-meshheading:7928489-Survival Analysis
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma.
|
|
pubmed:affiliation |
Radiation Oncology Branch, National Cancer Institute, Bethesda, MD 20892.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
